Table 6.

FDA-approved siRNA therapeutics.

Approval Date	Company	Therapeutic Name	Disease	Target	Delivery Route	Chemical Modification	Delivery System
August 2018	Alnylam	Patisiran	hATTR	TTR	Intravenous	2′-OMe modification	Second-generation LNPs
November 2019	Alnylam	Givosiran	AHP	ALAS1	Subcutaneous	PS linkages, 2′-OMe, 2′-F modification	GalNAc ligand conjugate
November 2020	Alnylam	Lumasiran	PH1	HAO1	Subcutaneous	PS linkages, 2′-OMe, 2′-F modification	GalNAc ligand conjugate
December 2020	Alnylam Novartis	Inclisiran	ACD	PCSK9	Subcutaneous	PS linkages, 2′-OMe, 2′-OMOE, 2′-F modification	GalNAc ligand conjugate

Note: Second-generation LNPs, containing CHOL, a polar lipid 1,2-distearoyl-sn-glycero-3-phosphocholine, PEGlated lipid PEG2000-C-DMG, ionizable amino lipid Dlin-MC3-DMA; AHP, acute hepatic porphyria; GalNAc, N-acetylgalactosamine.